Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 12, 2006, Pages 4011-4017

  Murillo, O ^a   Domenech A ^a   Garcia, A ^a   Tubau, F ^a   Cabellos, C ^a   Gudiol, F ^a   Ariza, J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLOXACILLIN; LEVOFLOXACIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BIOFILM; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; DRUG MEGADOSE; FOREIGN BODY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSTHESIS INFECTION; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CLOXACILLIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FOREIGN-BODY REACTION; HUMANS; MALE; METHICILLIN; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OXAZOLIDINONES; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 33845239419     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00523-06     Document Type: Article

References (48)

1. Andes, D., M. Van Ogtrop, J. Peng, and W. Craig. 2002. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob. Agents Chemother. 46:3484-3489.
2. Anwar, H., M. K. Dasgupta, and J. W. Costerton. 1990. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob. Agents Chemother. 34:2043-2046.
3. Bahl, D., D. A. Miller, I. Leviton, P. Gialanella, M. Wolin, W. Liu, R. Perkins, and M. H. Miller. 1997. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:1293-1297.
4. Cagni, A., C. Chuard, P. Vaudaux, J. Schrenzel, and D. P. Lew. 1995. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1655-1660.
5. Chapin-Robertson, K., and S. C. Edberg. 1991. Measurements of antibiotics in human body fluids: techniques and significance, p. 295-366. In V. Lorian (ed.). Antibiotics in laboratory medicine. Williams and Wilkins, New York, N.Y.
6. Chien, J. W., M. L. Kucia, and R. A. Salata. 2000. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30:146-151.
7. Chien, S., M. Rogge, L. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. Williams, C. Fowler, W. Cheng, and A. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
8. Chow, A. T., C. Fowler, R. Williams, N. Morgan, S. Kaminski, and J. Natarajan. 2001. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125.
9. Chuard, C., J. C. Lucet, P. Rohner, M. Herrmann, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1991. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J. Infect. Dis. 163:1369-1373.
10. Chuard, C., M. Herrmann, P. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:2611-2616.
11. Costerton, J. W., P. Stewart, and E. P. Greenberg. 1999. Bacterial biofilm: a common cause of persistent infections. Science 284:1318-1322.
12. Craig, W. 2001. Does the dose matter? Clin. Infect. Dis. 33(Suppl. 3):233-237.
13. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
14. Drancourt, M., A. Stein, J. N. Argenson, A. Zannier, G. Curvale, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus- infected orthopedic implants. Antimicrob. Agents Chemother. 37:1214-1218.
15. Drancourt, M., A. Stein, J. N. Argenson, R. Roiron, P. Groulier, and D. Raoult. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampin. J. Antimicrob. Chemother. 39:235-240.
16. Drusano, G. L., S. Preston, C. Fowler, M. Corrado, B. Weisinger, and J. Kahn. 2004. Relationship between fluoroquinolone area under curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597.
17. Eng, R. H., F. Padberg, S. Smith, E. Tan, and C. E. Cherubin. 1991. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob. Agents Chemother. 35:1824-1828.
18. Eng, R. H., S. M. Smith, M. Tillem, and C. Cherubin. 1985. Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch. Intern. Med. 145:146-148.
19. Firsov, A., I. Lubenko, S. Vostrov, Y. Portnoy, and S. Zinner. 2005. Anti-staphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob. Agents Chemother. 49:2642-2647.
20. Firsov, A., S. Zinner, S. Vostrov, Y. Portnoy, and I. Lubenko. 2002. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J. Antimicrob. Chemother. 50:533-539.
21. Forrest, A., D. Nix, C. Ballow, T. Goss, M. Birmingham, and J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
22. Fux, C. A., J. W. Costerton, P. Stewart, and P. Stoodley. 2005. Survival strategies of infectious biofilms. Trends Microbiol. 13:34-40.
23. Gilbert, P., P. J. Collier, and M. R. W. Brown. 1990. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob. Agents Chemother. 34:1865-1868.
24. James, J. K., S. Palmer, D. P. Levine, and M. J. Rybak. 1996. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob. Agents Chemother. 40:696-700.
25. Kucers, A., S. Crowe, M. L. Grayson, and J. Hoy. 1997. Rifampicin (rifampin), p. 676-708. In A. Kucers, S. Crowe, M. L. Grayson, and J. Hoy (ed.), The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs, 5th ed. Butterworth, Heinemann, Oxford, United Kingdom.
26. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
27. MacGowan, A. P. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J. Antimicrob. Chemother. 51(Suppl. 2):17-25.
28. Maduri Traczewski, M., D. Goldmann, and P. Murphy. 1983. In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. Antimicrob. Agents Chemother. 23:571-576.
29. Meka, V. G., S. Pillai, G. Sakoulas, C. Wennersten, L. Venkataraman, P. DeGirolami, G. Eliopoulos, R. Moellering, and H. S. Gold. 2004. Linezolid resistance in sequential Staphylococcus aureus isolates associated with T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J. Infect. Dis. 190:311-317.
30. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
31. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 5th ed., M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
32. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129.
33. Ryan, M., B. Hodges, G. R. Spencer, and S. M. Harding. 1982. Simultaneous comparison of three methods for assessing ceftazidime penetration into extravascular fluid. Antimicrob. Agents Chemother. 22:995-998.
34. Rybak, M. J., E. Bailey, K. Lamp, and G. W. Kaatz. 1992. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob. Agents Chemother. 36:1109-1114.
35. Sabath, L. D., C. Garner, C. Wilcox, and M. Finland. 1976. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob. Agents Chemother. 9:962-969.
36. Schaad, H. J., C. Chuard, P. Vaudaux, P. Rohner, F. A. Waldvogel, and D. P. Lew. 1994. Comparative efficacies of imipenem, oxacillin and vancomycin for therapy of chronic foreign body infection due to methicillin-susceptible and -resistant Staphylococcus aureus. J. Antimicrob. Chemother. 33:1191-1200.
37. Schentag, J., K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1):39-46.
38. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
39. Thomas, J., A. Forrest, S. Bhavnani, J. Hyatt, A. Cheng, C. Ballow, and J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
40. Trampuz, A., M. Wenk, Z. Rajacic, and W. Zimmerli. 2000. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob. Agents Chemother. 44:1352-1355.
41. Tuazon, C. U., M. Y. Lin, and J. N. Sheagren. 1978. In vitro activity of rifampin alone and in combination with nafcillin and vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 13:759-761.
42. Vaudaux, P., P. Francois, C. Bisognano, J. Schrenzel, and D. P. Lew. 2002. Comparison of levofloxacin, alatrofloxacin and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46:1503-1509.
43. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
44. Widmer, A. F., A. Gaechter, P. E. Ochsner, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
45. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
46. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections. JAMA 279:1537-1541.
47. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
48. Zimmerli, W., R. Frei, A. F. Widmer, and Z. Rajacic. 1994. Microbiological test to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.